item management s discussion and analysis of financial condition and results of operations results of operations revenues and operating income by segment for the years ended july are as follows revenues pharmaceutical systems    cardiopulmonary systems    total revenues    operating income loss pharmaceutical systems    cardiopulmonary systems   total operating income    operating income loss pharmaceutical systems cardiopulmonary systems total operating income loss compared with mmt s net income after taxes for the year ended july  was  or per share  on revenues of million compared to fiscal net income of  or per share  on revenues of million  reflecting a increase in revenues 
gross margins increased to in compared to in  due to higher volumes  a more favorable product mix  and the company s focus on manufacturing efficiencies 
operating expenses increased by from to  but improved as a percentage of net sales 
operating income and ebitda were and million  respectively  in  up from and million in due to improved overall operational efficiency 
within pharmaceutical systems  commercial sales were million in  higher than resulting primarily from increasing demand for the epipen and the introduction of the epipen pak tm 
government sales were million  lower than as sales to foreign governments decreased due to the timing of orders 
cardiopulmonary systems sales were million in  higher than reflecting higher telemedicine sales 
operating costs were million in  an increase of  from in addition to expanding investment in the prime marketing infrastructure  the company incurred expenses related to its initial efforts in developing a specialty pharmaceutical business unit 
the company expensed million  million and million on research and development activities in fiscal   and  respectively  excluding costs associated with customer funded projects 
the company expects research and development expenditures in fiscal to be significantly higher than the fiscal level  as efforts in this area accelerate 
non operating expenses in were million  lower than in the lower level in is a result of decreased interest expense  which was realized through a combination of lower debt balances and lower interest rates 
during the year  bank debt was reduced by million  while the company held million of cash at july  the income tax provision was million in  reflecting a effective rate  and million in  reflecting a effective rate 
the tax provision incorporates estimated benefits from utilization of operating loss carryforwards  offset by permanent book to tax differences and losses from foreign subsidiaries 
the company takes no consolidated tax benefit from the foreign losses  which for the year approximate million 
us pre tax income  taxed at the statutory rate after permanent and temporary differences  is higher than the consolidated pre tax income  which inflates the effective rate 
the impact of the foreign loss increases the effective tax rate for fiscal from to 
the increase in the effective rate from the prior year reflects the lower levels of net operating loss carryforwards to offset taxable income 
line of business discussion the pharmaceutical systems segment consists of commercial systems and government systems 
commercial systems operations include sales of meridian s highly recognized epipen product  used in the emergency treatment of allergic reactions to insect stings or bites  foods  drugs and other allergens  as well as idiopathic or exercise induced anaphylaxis 
within the pharmaceutical systems segment  commercial systems sales were million in  higher than in due to increased revenue from the epipen product  and increased r d services 
the level of demand of epipen has surpassed any previous period  and is expected to continue growing 
in march  the company launched the epipen pak  a new product packaging  where two epipen units and one epipen trainer are sold in one package 
the initial sales of the pak were primarily to stock the product with retailers  and it is not clear at this time what long term impact the epipen pak will have on overall unit demand 
epipen pak sales accounted for approximately of the total million of epipen revenues for the year 
contract research and development revenue was million in fiscal  higher than fiscal this business unit is expected to generate revenues in fiscal comparable to the company is moving forward on its establishment of a business unit to market branded specialty pharmaceuticals 
the company anticipates revenue growth from alliances that introduce new products in auto injectors and other delivery devices 
current new therapies under development or in negotiations include anti seizure drugs and other cns agents frequently prescribed by neurologists 
this business unit will maintain the sales  marketing and distribution of the future products  rather than selling through a distributor 
within government systems  the company has a long standing relationship with the dod  and also markets its products to foreign governments and state and local governments for domestic preparedness 
government systems revenues fell in compared to the prior year  to million 
the decrease reflects the cyclical nature of procurements  which are tied to the needs of us and allied military customers 
the company maintains a core business relationship with the dod through its industrial base maintenance contract  which was successfully renegotiated in the dod exercised the third year option of the contract in fiscal the contract calls for the retention by the company of key personnel and facilities to assure expertise for manufacturing auto injectors containing nerve agent antidotes  the management of the us army s shelf life extension program  the pre stocking of critical components to enhance readiness and mobilization capability  and new product orders 
this ibmc contributed of the total government systems revenue in fiscal  and is expected to generate at least million in revenues in fiscal for purposes of complying with terms of a contract  the company discloses that for the year ended july   sales of diazepam auto injectors to customers other than the us dod totaled  units 
the company maintains a homeland defense business unit within government systems 
revenues within the homeland defense unit were  in  higher than the previous year 
the company provides nerve agent antidote auto injector products to federal  state and local agencies  as well as foreign governments  through this unit 
these products are utilized to treat the effects of chemical nerve agent exposure 
the company believes that this market will continue to grow in response to the growing threat of terrorism and the increased preparedness focus  at the state and federal level  in response to the recent terrorist attacks in the us cardiopulmonary systems consists of the telemedicine line of business  as well as the company s prime ecg tm advanced electrocardiac mapping system 
the prime ecg tm system  which includes propriety software  offers the potential to significantly improve the non invasive diagnosis and treatment of heart disease 
the multi center clinical study was completed in fiscal  and an application was submitted to the food and drug administration for clearance to market prime in the united states on july  the company expects to receive fda clearance before the end of fiscal cardiopulmonary systems product revenues in were million  an increase from revenues of million 
the increase was due to increased telemedicine orders to support our customer  shahal  and its newly announced joint venture with philips medical 
this joint venture was formed to establish telemedicine monitoring services throughout europe 
compared with mmt s net income after taxes for the year ended july  was  or per share  on revenues of million compared to a fiscal net loss of  or per share  on revenues of million  reflecting a increase in revenues 
gross margins increased to in compared to in  when revenues and margins were negatively impacted by supplying free units of epipen as a result of the epipen recall 
operating expenses increased by from to  but decreased overall as a percentage of net sales 
this reflects the cost reduction efforts in place in versus the investment in research and development and a marketing infrastructure in operating income and ebitda were million and million  respectively  in  up from million and million in due to improved operations and the absence of recall obligations 
commercial systems sales were million in  higher than resulting from increasing demand for the epipen and the absence of recall obligations 
government systems sales were million  higher than as sales to foreign governments increased 
cardiopulmonary systems sales were million in  lower than reflecting lower telemedicine sales 
gross margins were of sales in compared to in the increased gross margins from to resulted primarily from higher production volume to support increased customer orders  and the recall obligations in the company shipped  free units of epipen in fiscal  both for actual units returned and to reimburse the distributor for cash costs 
while the direct cost of these free units was fully reserved  the lost revenue from those units depressed gross margins in that year operating costs were million in  an increase of million from the company initiated cost reduction programs in to compensate for the lower margins  while in  it was able to invest in the company s growth 
research and development and selling  general and administrative expenses both increased as product development efforts increased and a marketing infrastructure was enhanced to support corporate long term goals 
non operating expenses in were million  higher than in the higher level in is a result of decreased grant income from northern ireland 
the income tax provision was million in and in  reflecting a effective rate in the rate is a result of the company s utilization of net operating loss carryforwards  offset by permanent book to tax differences as a result of the amortization of intangibles 
line of business discussion within the pharmaceutical systems segment  commercial systems sales were million in  higher than in due to increased revenue from the epipen product 
in  free units of epipen were supplied to satisfy obligations from the may  product recall as discussed above 
it is estimated that the delivery of epipen units to reimburse recall cash costs depressed revenues by million 
government systems revenues increased by in over the prior year to million 
the increase resulted from higher sales to foreign governments  reflecting an expanding international market for the company s products 
cardiopulmonary systems product revenues in were million  a decrease from sales of million 
the decrease was due to a fluctuation in telemedicine orders 
liquidity and capital resources the company generated million of cash from operations in positive cash flows from operations consisted primarily of net income  non cash expenses for depreciation and amortization  and decreases in inventory and accounts receivable  which were partially offset by a decrease in accounts payable and other accrued liabilities 
investing activities used million of cash in fiscal primarily for capital additions and capitalized software costs 
financing activities used million primarily for the paydown of debt  offset by proceeds for issuance of common stock for option and warrant exercises 
working capital at july  was million  up from million at july  the increase is primarily attributable to higher cash balances  lower accounts payable and other accrued liabilities  and lower note payable to bank 
at july   accounts receivable were million  representing days sales outstanding  and inventories were million reflecting a turn over rate of times per year 
borrowings under the working capital lines were  leaving million available credit at july  recent accounting standards in june  the financial accounting standards board issued statements of financial accounting standards no 
 business combinations and no 
 goodwill and other intangible assets 
under the new rules  goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the new standards 
the company will adopt the new standards effective august   and anticipates that all amortization of goodwill excess of cost over net assets acquired as a charge to earnings will be eliminated 
amortization expense of million relating to excess of cost over net assets acquired was recorded during the year ended july  the impact of this change on fiscal results would have been per diluted weighted average share 
inflation in the view of management  the low levels of inflation in recent years and changing prices have had no significant effect on the company s financial condition and results of operations 
generally  the company is able to mitigate the effects of inflation on operating costs and expenses through price increases and productivity gains 
item a 
quantitative and qualitative disclosures about market risk the company s earnings are affected by fluctuations in the value of the us dollar  as compared to foreign currencies  as a result of transactions in foreign markets 
at july   the result of a uniform strengthening in the value of the dollar relative to the currencies in which the company s transactions are denominated would have resulted in an increase in net income of approximately  for the year ended july  this calculation assumes that each exchange rate would change in the same direction relative to the us dollar 
in addition to the direct effects of changes in exchange rates  which are a changed dollar value of the resulting sales  changes in exchange rates also affect the volume of sales or the foreign currency sales price as competitors services become more or less attractive 
the company s sensitivity analysis of the effects of changes in foreign currency exchange rates does not factor in a potential change in sales levels or local currency prices 
while the company is exposed to changes in interest rates as a result of its outstanding debt  the company does not currently utilize any derivative financial instruments related to its interest rate exposure 
total short term and long term debt outstanding at july  was million  consisting of million in variable rate borrowing and million in fixed rate borrowing 
at this level of variable rate borrowing  a hypothetical increase in interest rates would have decreased pre tax earnings by approximately  for the year ended july  at july   the fair value of the company s fixed rate debt outstanding was estimated at million 
a hypothetical change in interest rates would not result in a material change in the fair value of the company s fixed rate debt 

